Neurometrix (NASDAQ:NURO) Stock Price Crosses Above 50 Day Moving Average of $0.60

Neurometrix Inc (NASDAQ:NURO) shares passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.60 and traded as high as $0.51. Neurometrix shares last traded at $0.51, with a volume of 2,304 shares changing hands.

NURO has been the subject of several research analyst reports. ValuEngine raised shares of Neurometrix from a “hold” rating to a “buy” rating in a research note on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Neurometrix in a research note on Friday, April 26th. Finally, Zacks Investment Research raised shares of Neurometrix from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research note on Saturday, April 27th.

The company has a market capitalization of $4.55 million, a PE ratio of 3.69 and a beta of 0.74. The stock’s 50 day simple moving average is $0.59.

Neurometrix (NASDAQ:NURO) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.30. Neurometrix had a net margin of 6.36% and a return on equity of 11.77%. The firm had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.92 million. On average, equities analysts expect that Neurometrix Inc will post -0.35 earnings per share for the current year.

About Neurometrix (NASDAQ:NURO)

NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.

Featured Article: Forex

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with's FREE daily email newsletter.